Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform ™ drug optimization technology, today reported its financial ...

We are on track towards our goal of dosing the first patient in a Phase 1b clinical trial in the fourth quarter,” said Steve Ledger, CEO of Serina Therapeutics. "We also continue to advance our ...

Serina Therapeutics, Inc. ("Serina") (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform drug optimization ...

Tencent just shelled out over a billion dollars to become a 25% minority stakeholder in a new subsidiary that Ubisoft has created. The subsidiary will focus on three core IPs: Assassin's Creed, Far ...